Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04186585Phase 1Recruiting

Recommended Dose Estimation of BP-C2

Role: collaborator

NCT04298333Phase 1Completed

Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer

Role: lead

NCT03789019Phase 2Completed

BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment

Role: lead

NCT02783794Phase 2Completed

BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer

Role: lead

NCT01861509Phase 1Completed

BP-C1 in Metastatic Breast Cancer Patients

Role: lead

NCT03603197Phase 2Completed

BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer

Role: lead

NCT03627390Phase 2Completed

BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

Role: lead

All 7 trials loaded